Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Effectiveness of KDR2-2 Suspension Eyedrop on Neovascular Regression in the Treatment of Neovascular Glaucoma: an Exploratory Clinical Trial

Next Previous
X
Search
Trial Profile

Evaluation of Effectiveness of KDR2-2 Suspension Eyedrop on Neovascular Regression in the Treatment of Neovascular Glaucoma: an Exploratory Clinical Trial

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KDR2-2 (Primary)
  • Indications Neovascular glaucoma
  • Focus Therapeutic Use
  • Acronyms KDR-NVG

    • Most Recent Events

    • 04 Jan 2022 Phase amended from II to I. Study design changed from parallel, nonrandomized to single group assignment. 16mg/ml group and 4mg/ml group are merged into single arm. Time frame of primary outcome changed from Day 0, 7, 14, 21 and 28 to Day 0 and 7. In other outcomes, new measure "Changes of iris neovascularization" added and "Corneal endothelium count and Changes of anterior chamber structures" are removed, time frame changed from Day 0, 1, 7, 14, 21 and 28 to Day 0, 7 and 28.
    • 04 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Jan 2022.
    • 01 Sep 2021 Planned number of patients changed from 20 to 40.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top